View Filing Data

Document and Entity Information - shares	9 Months Ended
Sep. 30, 2016	Oct. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	MEDP
Entity Registrant Name	Medpace Holdings, Inc.
Entity Central Index Key	0001668397
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		40,719,891

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 14,636	$ 14,880
Restricted cash	3,363	2,857
Accounts receivable and unbilled, net (includes $4.6 million and $2.9 million with related parties at September 30, 2016 and December 31, 2015, respectively)	81,922	65,088
Prepaid expenses and other current assets	20,606	11,896
Total current assets	120,527	94,721
Property and equipment, net	41,342	37,512
Goodwill	660,981	660,981
Intangible assets, net	148,739	186,743
Deferred income taxes	135	157
Other assets	4,763	3,927
Total assets	976,487	984,041
Current liabilities:
Accounts payable	9,337	8,728
Accrued expenses	21,415	20,111
Pre-funded study costs (includes $4.0 million and $3.7 million with related parties at September 30, 2016 and December 31, 2015, respectively)	53,418	46,599
Advanced billings (includes $9.3 million and $10.2 million with related parties at September 30, 2016 and December 31, 2015, respectively)	67,662	51,051
Other current liabilities	4,763	7,528
Total current liabilities	156,595	134,017
Long-term debt, net, less current portion	154,614	377,882
Deemed landlord liability, less current portion	28,983	30,273
Deferred income tax liability	20,506	21,104
Other long-term liabilities	5,249	7,291
Total liabilities	365,947	570,567
Commitments and contingencies (see Note 10)
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2016; No shares authorized at December 31, 2015
Common stock - $0.01 par-value; 250,000,000 shares and 60,000,000 shares authorized at September 30, 2016 and December 31, 2015, respectively; 40,716,410 and 32,624,461 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	407	326
Additional paid-in capital	622,071	438,716
Accumulated deficit	(9,563)	(23,009)
Accumulated other comprehensive loss	(2,375)	(2,559)
Total shareholders’ equity	610,540	413,474
Total liabilities and shareholders’ equity	$ 976,487	$ 984,041

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, Unbilled services with related parties	$ 4.6	$ 2.9
Pre-funded study costs with related parties	4.0	3.7
Advanced billings with related parties	$ 9.3	$ 10.2
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	0
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	60,000,000
Common stock shares issued	40,716,410	32,624,461
Common stock shares outstanding	40,716,410	32,624,461

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Service revenue, net (includes $6.9 million and $6.1 million with related parties for the three months ended September 30, 2016 and 2015, respectively, and $19.3 million and $17.6 million with related parties for the nine months ended September 30, 2016 and 2015, respectively)	$ 94,812	$ 81,638	$ 275,245	$ 234,420
Reimbursed out-of-pocket revenue (includes $1.4 million and $1.3 million with related parties for the three months ended September 30, 2016 and 2015, respectively, and $4.3 million and $5.5 million with related parties for the nine months ended September 30, 2016 and 2015, respectively)	12,987	10,493	38,094	28,598
Total revenue	107,799	92,131	313,339	263,018
Operating expenses:
Direct costs, excluding depreciation and amortization	51,221	41,763	147,436	119,488
Reimbursed out-of-pocket expenses (includes $1.4 million and $1.3 million with related parties for the three months ended September 30, 2016 and 2015, respectively, and $4.3 million and $5.5 million with related parties for the nine months ended September 30, 2016 and 2015, respectively)	12,987	10,493	38,094	28,598
Selling, general and administrative	16,391	15,295	44,724	38,743
Depreciation	1,915	1,611	5,481	4,721
Amortization	12,668	15,774	38,004	50,017
Total operating expenses	95,182	84,936	273,739	241,567
Income from operations	12,617	7,195	39,600	21,451
Other (expense) income, net:
Miscellaneous (expense) income, net	(378)	50	(1,319)	(928)
Interest expense, net	(4,656)	(6,737)	(16,550)	(20,712)
Total other expense, net	(5,034)	(6,687)	(17,869)	(21,640)
Income (loss) before income taxes	7,583	508	21,731	(189)
Income tax provision (benefit)	2,547	641	8,285	(92)
Net income (loss)	$ 5,036	$ (133)	$ 13,446	$ (97)
Net income (loss) per share attributable to common shareholders:
Basic	$ 0.14	$ 0.00	$ 0.39	$ 0.00
Diluted	$ 0.13	$ 0.00	$ 0.39	$ 0.00
Weighted average common shares outstanding:
Basic	37,118	31,430	34,138	31,258
Diluted	37,623	31,430	34,365	31,258

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 13,446	$ (97)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	5,481	4,721
Amortization	38,004	50,017
Stock-based compensation expense	8,559	11,831
Amortization of debt issuance costs and discount	2,024	2,008
Deferred income tax benefit	(568)	(8,314)
Other	(256)	(140)
Changes in assets and liabilities:
Restricted cash	(506)	(1,220)
Accounts receivable and unbilled, net	(16,606)	5,973
Prepaid expenses and other current assets	(8,733)	(717)
Accounts payable	(943)	846
Accrued expenses	1,257	(113)
Pre-funded study costs	6,810	4,391
Advanced billings	16,560	(7,231)
Other assets and liabilities, net	(2,368)	(4,543)
Net cash provided by operating activities	62,161	57,412
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures	(7,843)	(4,688)
Other	83	28
Net cash used in investing activities	(7,760)	(4,660)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for common stock issuance costs	(2,719)	0
Proceeds from stock option exercises	452	246
Payment of debt	(225,054)	(66,037)
Payment of deemed landlord liability	(1,129)	(930)
Proceeds from common stock issued, net of underwriters discount	173,578	608
Net cash used in financing activities	(54,872)	(66,113)
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	227	(292)
DECREASES IN CASH AND CASH EQUIVALENTS	(244)	(13,653)
CASH AND CASH EQUIVALENTS — Beginning of period	14,880	54,285
CASH AND CASH EQUIVALENTS — End of period	$ 14,636	$ 40,632

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission on August 11, 2016 (the “Prospectus”). The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by GAAP. Stock Split On July 25, 2016, the Board of Directors (the “Board”) of the Company approved, and made legally effective, a 1-for-1.35 reverse stock split of the Company’s common stock. All share, stock option and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. The Company will make a cash payment to shareholders for all fractional shares which would have otherwise been required to be issued as a result of the reverse stock split. There was no change in the par value of the Company’s common stock. Initial Public Offering On August 11, 2016, the Company's common stock began trading on the NASDAQ Global Select Market under the symbol "MEDP". On August 16, 2016, the Company completed its initial public offering (“IPO”) of its common stock at a price to the public of $23.00 per share. The Company issued and sold 8,050,000 shares of common stock in the IPO, including 1,050,000 common shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares. The IPO raised net proceeds of approximately $173.6 million after deducting underwriting discounts and commissions. As contemplated in the Company’s Prospectus, the net proceeds from the IPO, along with cash on hand, were used to repay $175 million of outstanding borrowings under the Senior Secured Term Loan Facility (as defined below) and $2.7 million of offering expenses. Recently Issued Accounting Standards In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. Early adoption is permitted, but all guidance must be adopted in the same period. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The new guidance adds Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Under current U.S. GAAP, companies generally recognize credit losses when it is probable that the loss has been incurred. The revised guidance will remove all recognition thresholds and will require companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 will be applied on a prospective basis for fiscal years and interim periods beginning after December 15, 2019, with early adoption permitted for fiscal years beginning and interim periods beginning after December 15, 2018. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASUs’ 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of ASU 2014-09 by one year. The Company will adopt the clarified guidance in ASUs’ 2016-12, 2016-10, 2016-08 by January 1, 2018, as required. The Company is currently evaluating the impact of this new standard on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new guidance is intended to simplify certain aspects of accounting for share-based payments to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Early adoption is permitted, but all guidance must be adopted in the same period. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 will be applied on a modified retrospective basis and to each prior reporting period presented and is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements.

Net Income (Loss) Per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

(2) Net Income (Loss) Per Share

Basic and diluted earnings per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding, including outstanding participating securities. Diluted net income (loss) per share is similar to basic net income (loss) per share, but adjusts for the potential issuance of common shares. The Company’s restricted stock awards (“RSAs”) contain non-forfeitable rights or dividend equivalents and participate in periods of net income but are not contractually obligated to share in the Company’s losses. As a result, RSAs are included in the number of shares in our basic and diluted EPS in periods of net income but are excluded in the number of shares in our basic and diluted EPS in periods of net loss.

The following table reconciles the basic to diluted weighted average shares outstanding (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2016		2015		2016		2015
Basic weighted average common shares outstanding		37,118		31,430		34,138		31,258
Effect of dilutive securities		505		-		227		-
Diluted weighted average common shares outstanding		37,623		31,430		34,365		31,258
Anti-dilutive shares		62		-		26		-

The anti-dilutive shares disclosed above were calculated using the treasury stock method. During the nine months ended September 30, 2016, the Company had stock options that were excluded due to the exercise price exceeding the average fair value of the Company’s common stock during the period. During the three and nine months ended September 30, 2015, the Company had stock options that were excluded due to the Company’s net loss positions.

Intangible Assets, Net

9 Months Ended

Sep. 30, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

(5) Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	As of
	September 30,			December 31,
	2016			2015
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		2,505			2,505
Total finite-lived intangible assets		274,661			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(56,448	)		(26,991	)
Developed technologies		(27,238	)		(19,066	)
Other		(1,252	)		(877	)
Total accumulated amortization		(157,568	)		(119,564	)
Total finite-lived intangible assets, net		117,093			155,097
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	148,739		$	186,743

As of September 30, 2016, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):

	Amortization
Remainder of 2016	$	12,668
2017		37,790
2018		29,371
2019		14,639
2020		7,797
Later years		14,828
	$	117,093

Debt

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Debt

(7) Debt

Debt consisted of the following (in thousands):

	As of
	September 30,			December 31,
	2016			2015

Term loan	$	165,000		$	390,000
Capital lease		6			59
		165,006			390,059
Less unamortized discount		(1,700	)		(1,984	)
Less unamortized term loan debt issuance costs		(8,686	)		(10,134	)
Less current portion of long-term debt		(6	)		(59	)
Long-term debt, net, less current portion	$	154,614		$	377,882

Principal payments on debt are due as follows (in thousands):

2016 (remaining)	$	6
2017	-
2018	-
2019	-
2020 and thereafter	165,000
Total	$	165,006

The estimated fair value of the Company’s term loan based on Level 1 quoted market prices approximates $164.1 million and $386.3 million as of September 30, 2016 and December 31, 2015, compared to the carrying value of $163.3 million and $388.0 million.

Credit Agreement

On April 1, 2014, the Company entered into a new credit agreement (the “Senior Secured Credit Agreement”), consisting of a $530 million term loan (“Senior Secured Term Loan Facility”) and a $60 million revolving credit facility ("Senior Secured Revolving Credit Facility" and together with the Senior Secured Term Loan Facility, the “Senior Secured Credit Facilities”). The Senior Secured Term Loan Facility expires in April 2021 and the Senior Secured Revolving Credit Facility portion expires in April 2019. The Senior Secured Credit Agreement is guaranteed by the Company and its subsidiaries and is subject to customary covenants relating to financial ratios and restrictions on certain types of transactions, including restricting the Company's ability to incur additional indebtedness, acquire and dispose of assets, make investments, pay dividends, or engage in mergers and acquisitions.

Borrowings under the Senior Secured Credit Agreement bear interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio is greater than 4.75:1.00, or 3.75% if our total net leverage ratio is less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate shall be deemed to be no less than 1.00% per annum; (b) a base rate, which is defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio is greater than 4.75:1.00, or 2.75% if our total leverage ratio is less than or equal to 4.75:1.00; provided that the base rate shall be deemed to be no less than 2.00% per annum. We may voluntarily prepay outstanding loans under the Senior Secured Credit Agreement without premium or penalty. As of September 30, 2016, the interest rate applicable on the term loan was the Eurocurrency minimum floor interest rate of 4.75%.

In addition, the Company is required to pay to the lenders a commitment fee of 0.5% quarterly for unused commitments on the Senior Secured Revolving Credit Facility, subject to a step-down to 0.375% based upon achievement of a certain leverage ratio as defined within the Senior Secured Credit Agreement. At September 30, 2016 the Company had no outstanding borrowings under the Senior Secured Revolving Credit Facility, resulting in $60.0 million in undrawn capacity available under the Senior Secured Revolving Credit Facility. In addition, the Company had less than $0.1 million in letters of credit outstanding, which are secured by the Senior Secured Revolving Credit Facility at September 30, 2016.

Also within the Senior Secured Credit Agreement, if we have drawn greater than 30% of the commitments under the Senior Secured Credit Agreement as of the last date of any quarter, then we are required to report compliance with a financial covenant that is tested at the end of each quarter. This financial covenant requires us to maintain a net debt to consolidated EBITDA leverage ratio (as defined under the Senior Secured Credit Agreement) of less than or equal to 8.00:1.00 for any fiscal quarter ending on or prior to March 31, 2016 and 7.50:1.00, thereafter. As of September 30, 2016, we were in compliance with all covenants under our Senior Secured Credit Agreement.

Shareholder’s Equity and Stock-Based Compensation

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Shareholder’s Equity and Stock-Based Compensation

(8) Shareholder’s Equity and Stock-Based Compensation

Authorized Shares

On August 16, 2016 the Company amended its Certificate of Incorporation in connection with the closing of its IPO to increase the authorized number of shares of common stock to 250,000,000 and to authorize 5,000,000 shares of preferred stock that may be issued from time to time by the Company’s Board.

Stock-Based Compensation

On August 11, 2016 in connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards. The number of shares registered and available for grant under the 2016 Plan is 6,000,000. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of our common stock at the date of grant and option terms are not expected to exceed ten years. The 2016 Plan expires in 2026, except for awards then outstanding, and is administered by the Board. All Awards granted at the IPO or thereafter were or will be issued under the 2016 Plan.

We satisfy stock option exercises and vested stock awards with newly issued shares. Shares available for future stock compensation grants totaled 5.4 million at September 30, 2016.

The Company granted 45,923 Awards under the 2014 Plan, consisting of 34,812 stock options vesting equally over four years and 11,111 fully-vested shares, during the nine months ended September 30, 2016. The Company also granted 643,680 stock options under the 2016 Plan during the nine months ended September 30, 2016, consisting of 626,650 stock options vesting after four years and 17,030 stock options with one-third vesting on October 31, 2016, and the remainder vesting in eight equal monthly installments beginning in November 2016.

Option Awards Modification

As a result of the Company’s IPO, a condition of all outstanding stock options issued before August 10, 2016 under the 2014 Plan that previously required the exchange of the shares issued for incentive units in the equity of a non-consolidated related party was dissolved. All future exercises of options issued pursuant to the 2014 Plan will now settle in shares of the Company. As a result of the modification in the settlement condition, the options will now be equity-classified instruments and changes in the fair value of the stock compensation liability that occur during the requisite service period are no longer recognized. According to the authoritative guidance for stock-based compensation, at modification the Company should recognize additional stock-based compensation expense in the amount of the incremental fair value of the modified award. As a result, the Company recognized $3.1 million of incremental stock-based compensation expense during the three months ended September 30, 2016. In addition, the $10.5 million stock-based compensation liability associated with the modified stock options was reclassified to additional paid-in capital as a result of the change to equity classification. The stock-based compensation liability was $0.0 at September 30, 2016. The stock-based compensation liability was $3.6 million at December 31, 2015, of which $1.7 million was included in Other current liabilities and $1.9 million was included in Other long-term liabilities in the condensed consolidated balance sheet.

Stock-based compensation expense recognized in the condensed consolidated statements of operations related to the Awards is summarized below (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Direct costs, excluding depreciation and amortization	$	2,500	$	1,031	$	4,974	$	4,212
Selling, general and administrative		1,784		5,895		3,585		7,619
Total stock-based compensation expense	$	4,284	$	6,926	$	8,559	$	11,831

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	(11) Related Party Transactions Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $0.2 million existed at September 30, 2016 and December 31, 2015, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the condensed consolidated balance sheets, respectively, depending on the contractual repayment date. Management Fees In conjunction with the IPO, the Advisory Services Agreement with Cinven Capital Management (V) General Partner Limited (“Cinven”) expired. Subsequent to the IPO, the Company will pay fees for director services provided by Cinven employees that are members of the Company’s Board of Directors and any related committees. The director fees will be paid directly to Cinven in accordance with the Company’s non-employee director compensation policy. During the three and nine months ended September 30, 2016, the Company incurred management fees to Cinven of less than $0.1 million and $0.2 million, respectively, related travel expenses of $0.0 million and less than $0.1 million, respectively, and director fees of less than $0.1 million and less than $0.1 million, respectively. During the three and nine months ended September 30, 2015, the Company incurred management fees to Cinven of $0.1 million and $0.2 million, respectively, and related travel expenses of less than $0.1 million and $0.1 million, respectively. As of September 30, 2016 and December 31, 2015, the Company had outstanding accounts payable to Cinven of less than $0.1 million and $0.1 million, respectively. Service Agreements Medpace Investors LLC, a noncontrolling shareholder of the Company that is owned by employees of the Company and managed by our chief executive officer, has a majority ownership interest in Symplmed Pharmaceuticals, LLC (“Symplmed”), a private pharmaceutical development company. In addition, the chief executive officer and other executives of the Company are board members of Symplmed. The Company has operated under a Master Services Agreement (“MSA”) with Symplmed since 2013 (amended in 2014) to perform clinical trials and related activities. Certain task orders governed by this arrangement were amended in the third quarter of 2016, changing the fee structure from unitized in nature to time and materials and revised pricing to more appropriately reflect market pricing based on the Company’s leveraging of this work to develop and enhance certain new service capabilities. The Company has evaluated its relationship with Symplmed and concluded that Symplmed is not a variable interest entity because the Company has no direct ownership interest or relationship other than the MSA. During the three months ended September 30, 2016 and 2015, the Company recognized negative service revenue adjustments from Symplmed of $0.4 million and service revenue of $0.1 million, respectively, and during the nine months ended September 30, 2016 and 2015, the Company recognized negative service revenue adjustments from Symplmed of less than $0.1 million and service revenue of $0.6 million, respectively, in the Company’s condensed consolidated statements of operations. The chief executive officer of the Company is a member of Coherus BioSciences, Inc.’s (“Coherus”) board of directors. The Company has secured an agreement to perform Phase I through Phase III clinical trial work for certain Coherus “bio-similar” drug compounds. The agreement provides for a minimum fee commitment for clinical trial services and is cancelable without cause by either party upon 30 days prior notice. During the three months ended September 30, 2016 and 2015, the Company recognized service revenue from Coherus of $6.8 million and $5.9 million, respectively, and during the nine months ended September 30, 2016 and 2015, the Company recognized service revenue from Coherus of $18.2 million and $16.8 million, respectively, in the Company’s condensed consolidated statements of operations. As of September 30, 2016 and December 31, 2015, respectively, the Company had accounts receivable from Coherus of $4.4 million and $2.0 million recorded in the condensed consolidated balance sheets, respectively. As of September 30, 2016 and December 31, 2015, respectively, the Company had, from Coherus, $7.6 million and $8.4 million of Advanced billings and $3.8 million and $3.5 million of Pre-funded study costs, in the condensed consolidated balance sheets. Certain executives and employees of the Company, including the chief executive officer, have equity investments in Xenon, a clinical-stage biopharmaceutical company. In addition, a Medpace employee was a director of Xenon until May 2015. During July 2015 the Company and Xenon entered into an amended MSA agreement for the Company to provide certain clinical development services. The Company recognized service revenue from Xenon of $0.4 million during the three months ended September 30, 2016, and $0.8 million and $0.1 million during the nine months ended September 30, 2016 and 2015, respectively, in the Company’s condensed consolidated statements of operations. As of September 30, 2016 and December 31, 2015, respectively, the Company had, from Xenon, $1.7 million and $1.8 million of Advanced billings and $0.3 million and $0.2 million of Pre-funded study costs, in the condensed consolidated balance sheets. Leased Real Estate Headquarters Lease The Company has entered into operating leases for its corporate headquarters and a storage space facility with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease for headquarters is for an initial term of twelve years through November 2022 with a renewal option for one 10-year term at prevailing market rates. The lease for storage space was through June 2016 and is currently being leased on a month to month basis. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. Lease expense recognized for each of the three month periods ended September 30, 2016 and 2015 was $0.5 million, and lease expense recognized for each of the nine month periods ended September 30, 2016 and 2015 was $1.6 million. The lease expense was allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the condensed consolidated statements of operations. Deemed Assets and Deemed Landlord Liabilities The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase and at completion. Accordingly, the Company reflected the buildings and related liabilities as deemed assets from landlord building construction in Property and equipment, net, Other current liabilities, and Deemed landlord liabilities, respectively, on the condensed consolidated balance sheets. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10-year option to extend the lease term. The deemed assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease. Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties. Accretion expense is being recorded over the term of the lease as a component of Interest expense, net in the Company’s condensed consolidated statements of operations. The Company paid $0.9 million during the three months ended September 30, 2016 and 2015, respectively, and $2.8 million and $2.5 million during the nine months ended September 30, 2016 and 2015, respectively. The current and long-term portions of the Deemed landlord liability at September 30, 2016 were $1.6 million and $29.0 million, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2015 were $1.6 million and $30.3 million, respectively. The Company has recognized deemed assets, net of $18.5 million and $19.8 million at September 30, 2016 and December 31, 2015, respectively, in the condensed consolidated balance sheets. Travel Services The Company incurs expenses for travel services for company executives provided by a private aviation charter company that is owned by the chief executive officer and the senior vice president of operations of the Company (“private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $0.3 million and $0.2 million during the three months ended September 30, 2016 and 2015, respectively, related to these travel services, and $0.8 million and $0.7 million during the nine months ended September 30, 2016 and 2015, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s condensed consolidated statements of operations.

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission on August 11, 2016 (the “Prospectus”). The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by GAAP.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. Early adoption is permitted, but all guidance must be adopted in the same period. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The new guidance adds Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Under current U.S. GAAP, companies generally recognize credit losses when it is probable that the loss has been incurred. The revised guidance will remove all recognition thresholds and will require companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 will be applied on a prospective basis for fiscal years and interim periods beginning after December 15, 2019, with early adoption permitted for fiscal years beginning and interim periods beginning after December 15, 2018. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASUs’ 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of ASU 2014-09 by one year. The Company will adopt the clarified guidance in ASUs’ 2016-12, 2016-10, 2016-08 by January 1, 2018, as required. The Company is currently evaluating the impact of this new standard on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new guidance is intended to simplify certain aspects of accounting for share-based payments to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Early adoption is permitted, but all guidance must be adopted in the same period. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 will be applied on a modified retrospective basis and to each prior reporting period presented and is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements.

Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	As of
	September 30,			December 31,
	2016			2015
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		2,505			2,505
Total finite-lived intangible assets		274,661			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(56,448	)		(26,991	)
Developed technologies		(27,238	)		(19,066	)
Other		(1,252	)		(877	)
Total accumulated amortization		(157,568	)		(119,564	)
Total finite-lived intangible assets, net		117,093			155,097
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	148,739		$	186,743

Schedule of Estimated Amortization Expense of Intangible Assets

As of September 30, 2016, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):

	Amortization
Remainder of 2016	$	12,668
2017		37,790
2018		29,371
2019		14,639
2020		7,797
Later years		14,828
	$	117,093

Debt (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following (in thousands):

	As of
	September 30,			December 31,
	2016			2015

Term loan	$	165,000		$	390,000
Capital lease		6			59
		165,006			390,059
Less unamortized discount		(1,700	)		(1,984	)
Less unamortized term loan debt issuance costs		(8,686	)		(10,134	)
Less current portion of long-term debt		(6	)		(59	)
Long-term debt, net, less current portion	$	154,614		$	377,882

Schedule of Principal Payments on Debt Due

Principal payments on debt are due as follows (in thousands):

2016 (remaining)	$	6
2017	-
2018	-
2019	-
2020 and thereafter	165,000
Total	$	165,006

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Debt - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
Debt - Additional Information (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Apr. 01, 2014
Debt Instrument [Line Items]
Carrying value of debt	$ 165,006,000		$ 165,006,000
Eurocurrency minimum floor interest rate	4.75%		4.75%
Description of variable interest rate basis			Borrowings under the Senior Secured Credit Agreement bear interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio is greater than 4.75:1.00, or 3.75% if our total net leverage ratio is less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate shall be deemed to be no less than 1.00% per annum; (b) a base rate, which is defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio is greater than 4.75:1.00, or 2.75% if our total leverage ratio is less than or equal to 4.75:1.00; provided that the base rate shall be deemed to be no less than 2.00% per annum.
Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			4.00%
Federal Funds Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			0.50%
Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.00%
Base Rate \| Senior Secured Credit Agreement Bear Interest - Scenario 1
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.00%
Base Rate \| Senior Secured Credit Agreement Bear Interest - Scenario 2
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			3.00%
Maximum \| Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			3.75%
Debt instrument, total net leverage ratio			475.00%
Debt instrument, deemed interest rate			1.00%
Maximum \| Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.75%
Debt instrument, total net leverage ratio			475.00%
Debt instrument, deemed interest rate			2.00%
Minimum \| Eurocurrency Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio			475.00%
Minimum \| Base Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio			475.00%
Senior Secured Credit Agreement
Debt Instrument [Line Items]
Debt instrument financial covenant, description			if we have drawn greater than 30% of the commitments under the Credit Agreement as of the last date of any quarter, then we are required to report compliance with a financial covenant that is tested at the end of each quarter. This financial covenant requires us to maintain a net debt to consolidated EBITDA leverage ratio (as defined under the Credit Agreement) of less than or equal to 8.00:1.00 for any fiscal quarter ending on or prior to March 31, 2016 and 7.50:1.00, thereafter. As of June 30, 2016, we were in compliance with all covenants under our Credit Agreement.
Debt instrument financial covenant, net debt to consolidated EBITDA leverage ratio	750.00%	800.00%
Senior Secured Credit Agreement \| Minimum
Debt Instrument [Line Items]
Debt instrument financial covenant, percentage of drawn amount on commitments under borrowings			30.00%
Senior Secured Credit Agreement \| Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 60,000,000
Expiration date			2019-04
Outstanding borrowings	$ 0		$ 0
Undrawn capacity			$ 60,000,000
Senior Secured Credit Agreement \| Senior Secured Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee percentage			0.50%
Outstanding letters of credit	100,000		$ 100,000
Senior Secured Credit Agreement \| Senior Secured Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee percentage			0.375%
Term Loan
Debt Instrument [Line Items]
Carrying value of debt	163,300,000		$ 163,300,000	$ 388,000,000
Term Loan \| Level 1
Debt Instrument [Line Items]
Estimated fair value of debt	$ 164,100,000		$ 164,100,000	$ 386,300,000
Senior Secured Term Loan Facility \| Senior Secured Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 530,000,000
Expiration date			2021-04

Shareholder's Equity and Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Aug. 16, 2016	Aug. 11, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized	250,000,000	250,000,000	250,000,000		60,000,000
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000		0
Incremental stock based compensation expense	$ 3,100,000
Stock-based compensation liability reclassified to additional paid in capital		$ 10,500,000
Stock-based compensation liability	$ 0.0	$ 0.0			$ 3,600,000
Other Current Liabilities
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation liability					1,700,000
Other Long-Term Liabilities
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation liability					$ 1,900,000
2016 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares registered and available for grant				6,000,000
Plan expiration year		2026
Shares available for future stock compensation grants	5,400,000	5,400,000
Stock options granted		643,680
2016 Incentive Award Plan \| Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		626,650
Award vesting period		4 years
2016 Incentive Award Plan \| Vesting on October 31, 2016 and Eight equal monthly Installments
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		17,030
Vesting percentage		33.00%
Award vesting description		stock options with one-third vesting on October 31, 2016, and the remainder vesting in eight equal monthly installments beginning in November 2016
2016 Incentive Award Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation option terms		10 years
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards granted		45,923
Award vesting period		4 years
2014 Equity Incentive Plan \| Vesting Equally Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		34,812
2014 Equity Incentive Plan \| Fully Vested
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted		11,111

Related Party Transactions - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) RenewalOption Agreement Building	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Related Party Transaction [Line Items]
Service revenue with related parties	$ 6,900,000	$ 6,100,000	$ 19,300,000	$ 17,600,000
Advanced billings	67,662,000		67,662,000		$ 51,051,000
Pre-funded study costs with related parties	4,000,000		4,000,000		3,700,000
Deemed landlord liability, long-term portions	28,983,000		28,983,000		30,273,000
Cinven
Related Party Transaction [Line Items]
Management fees expense with related party		100,000	200,000	200,000
Travel expenses with related party	0			100,000
Accounts payable to related party					100,000
Maximum \| Cinven
Related Party Transaction [Line Items]
Management fees expense with related party	100,000
Travel expenses with related party		100,000	100,000
Director fees with related party	100,000		100,000
Accounts payable to related party	100,000		100,000
Employee Loans \| Prepaid Expenses and Other Current Assets
Related Party Transaction [Line Items]
Employee advances receivables	200,000		200,000
Employee Loans \| Other Assets
Related Party Transaction [Line Items]
Employee advances receivables					200,000
Service Agreements \| Symplmed
Related Party Transaction [Line Items]
Service revenue with related parties		100,000		600,000
Negative service revenue adjustments	(400,000)
Service Agreements \| Coherus Bio Sciences Inc
Related Party Transaction [Line Items]
Service revenue with related parties	6,800,000	5,900,000	$ 18,200,000	16,800,000
Service agreement cancellation notice period			30 days
Receivables from related party	4,400,000		$ 4,400,000		2,000,000
Advanced billings	7,600,000		7,600,000		8,400,000
Pre-funded study costs with related parties	3,800,000		3,800,000		3,500,000
Service Agreements \| Xenon
Related Party Transaction [Line Items]
Service revenue with related parties	400,000		800,000	100,000
Advanced billings	1,700,000		1,700,000		1,800,000
Pre-funded study costs with related parties	300,000		300,000		200,000
Service Agreements \| Maximum \| Symplmed
Related Party Transaction [Line Items]
Negative service revenue adjustments			$ (100,000)
Leased Real Estate \| Chief Executive Officer
Related Party Transaction [Line Items]
Term of lease			12 years
Lease expiration period			2022-11
Number of lease renewal, 10-year option \| RenewalOption			1
Lease term upon renewal			10 years
Lease expense recognized	500,000	500,000	$ 1,600,000	1,600,000
Storage space lease basis			month to month basis
Leased Real Estate \| Chief Executive Officer And Immediate Family
Related Party Transaction [Line Items]
Term of lease			15 years
Number of lease renewal, 10-year option \| RenewalOption			1
Lease term upon renewal			10 years
Number of lease agreements \| Agreement			2
Number of buildings \| Building			2
Lease occupancy year			2012
Lease expiration year			2027
Accretion expense paid	900,000	900,000	$ 2,800,000	2,500,000
Deemed landlord liability, current	1,600,000		1,600,000		1,600,000
Deemed landlord liability, long-term portions	29,000,000		29,000,000		30,300,000
Leased Real Estate \| Property and Equipment, Net \| Chief Executive Officer And Immediate Family \| Building
Related Party Transaction [Line Items]
Deemed assets, net	18,500,000		18,500,000		$ 19,800,000
Travel Services \| Chief Executive Officer
Related Party Transaction [Line Items]
Travel expenses with related party	$ 300,000	$ 200,000	$ 800,000	$ 700,000

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Service revenue with related parties	$ 6.9	$ 6.1	$ 19.3	$ 17.6
Reimbursed out-of-pocket revenue with related parties	1.4	1.3	4.3	5.5
Reimbursed out-of-pocket expenses with related parties	$ 1.4	$ 1.3	$ 4.3	$ 5.5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 5,036	$ (133)	$ 13,446	$ (97)
Other comprehensive income (loss)
Foreign currency translation adjustments, net of taxes	176	(127)	184	(522)
Comprehensive income (loss)	$ 5,212	$ (260)	$ 13,630	$ (619)

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(3) Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of September 30, 2016. There were no transfers between Level 1, Level 2 or Level 3 during the three or nine months ended September 30, 2016 or September 30, 2015. Non-recurring Fair Value Measurements Certain assets are measured on the accompanying interim condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets, which include indefinite-lived intangible assets and goodwill, are tested for impairment annually during the fourth quarter or when a triggering event occurs. Total assets carried on the balance sheet that are not remeasured to fair value on a recurring basis, identified as Level 3 measurements, as of September 30, 2016 are $692.6 million, comprised of $661.0 million of goodwill and $31.6 million of identified indefinite-lived intangible assets.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(9) Income Taxes The Company’s effective income tax rate was 38.1% and 48.7% for the nine months ended September 30, 2016 and 2015, respectively. The Company’s effective income tax rate for the nine months ended September 30, 2016 varied from the U.S. statutory rate of 35.0% primarily due to the impact of domestic and foreign uncertain tax positions.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(10) Commitments and Contingencies Legal Proceedings The Company is involved in legal proceedings from time to time in the ordinary course of its business, including employment claims and claims related to other business transactions. The Company cannot predict with certainty the outcome of such proceedings, but it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of September 30, 2016 and December 31, 2015. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, the Company believes that such potential losses were immaterial as of September 30, 2016.

Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands			9 Months Ended
	Aug. 16, 2016 USD ($) $ / shares shares	Jul. 25, 2016	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)
Basis Of Presentation [Line Items]
Reverse stock split of common stock		0.74
Offering expenses			$ 2,719	$ 0
Senior Secured Term Loan Facility
Basis Of Presentation [Line Items]
Repayments of outstanding borrowings	$ 175,000
Initial Public Offering
Basis Of Presentation [Line Items]
Shares issued and sold, price per share \| $ / shares	$ 23.00
Shares issued and sold \| shares	8,050,000
Net proceeds from issuance IPO	$ 173,600
Offering expenses	$ 2,700
Exercise of Underwriters' Option
Basis Of Presentation [Line Items]
Shares issued and sold \| shares	1,050,000

Fair Value Measurements - Additional Information (Details) - Non-recurring - Level 3 $ in Millions	Sep. 30, 2016 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Asset fair value	$ 692.6
Goodwill	661.0
Indefinite-lived intangible assets	$ 31.6

Accounts Receivable And Unbilled, Net - Schedule of Accounts Receivable and Unbilled, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accounts Notes And Loans Receivable Net Current [Abstract]
Accounts receivable	$ 57,136	$ 40,721
Unbilled	26,891	26,091
Less allowance for doubtful accounts	(2,105)	(1,724)
Total accounts receivable and unbilled, net	$ 81,922	$ 65,088

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Finite-lived intangible assets:
Total finite-lived intangible assets	$ 274,661	$ 274,661
Accumulated amortization:
Total accumulated amortization	(157,568)	(119,564)
Total finite-lived intangible assets, net	117,093	155,097
Trade name (indefinite-lived)	31,646	31,646
Total intangible assets, net	148,739	186,743
Backlog
Finite-lived intangible assets:
Total finite-lived intangible assets	72,630	72,630
Accumulated amortization:
Total accumulated amortization	(72,630)	(72,630)
Customer Relationships
Finite-lived intangible assets:
Total finite-lived intangible assets	145,051	145,051
Accumulated amortization:
Total accumulated amortization	(56,448)	(26,991)
Developed Technologies
Finite-lived intangible assets:
Total finite-lived intangible assets	54,475	54,475
Accumulated amortization:
Total accumulated amortization	(27,238)	(19,066)
Other
Finite-lived intangible assets:
Total finite-lived intangible assets	2,505	2,505
Accumulated amortization:
Total accumulated amortization	$ (1,252)	$ (877)

Intangible Assets, Net - Schedule of Estimated Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2016	$ 12,668
2017	37,790
2018	29,371
2019	14,639
2020	7,797
Later years	14,828
Total finite-lived intangible assets, net	$ 117,093	$ 155,097

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities And Other Liabilities [Abstract]
Employee compensation and benefits	$ 18,364	$ 17,195
Other	3,051	2,916
Total accrued expenses	$ 21,415	$ 20,111

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, gross	$ 165,006	$ 390,059
Less unamortized discount	(1,700)	(1,984)
Less unamortized term loan debt issuance costs	(8,686)	(10,134)
Less current portion of long-term debt	(6)	(59)
Long-term debt, net, less current portion	154,614	377,882
Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	165,000	390,000
Capital Lease
Debt Instrument [Line Items]
Long-term debt, gross	$ 6	$ 59

Income Taxes - Additional Information (Details)	9 Months Ended
Income Taxes - Additional Information (Details)	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Effective income tax rate	38.10%	48.70%
U.S. statutory rate	35.00%